GO:0002839 positive regulation of immune response to tumor cell: Immune Evasion Mechanisms, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0002839 describes any process that activates or increases the frequency, rate, or extent of an immune response directed against tumor cells [1,2].
• Positive regulation of anti-tumor immunity requires coordinated antigen presentation, co-stimulation, cytokine signaling, and metabolic support of effector T cells [3,4].
• Tumors evade this process through mechanisms such as autophagy-mediated MHC-I degradation, aberrant glycosylation of B7H3, and impaired monocyte-mediated T cell stimulation [1,5,8].
• Checkpoint pathways, particularly PD-1/PD-L1, act as dominant negative regulators of this GO term, and their blockade restores tumor cell killing [2,7].
• MHC-II expression on tumor cells can either promote or suppress anti-tumor immunity depending on context, highlighting the need for precise models.
• CRISPR knockout, knock-in, and overexpression models are essential to dissect causal genes within this process and to validate therapeutic targets [1,5,8].
Description
GO:0002839, positive regulation of immune response to tumor cell, is a biological process that encompasses all molecular and cellular events that enhance the immune system's ability to recognize and eliminate malignant cells [1,2]. This term is critical for understanding how the immune system can be harnessed to fight cancer, and how tumors subvert these mechanisms to evade destruction [1,8]. Research into this process has direct implications for cancer immunotherapy, vaccine development, and the identification of biomarkers of response to immune checkpoint blockade [2,7]. The QuickGO definition states: Any process that activates or increases the frequency, rate, or extent of an immune response to tumor cell [1,2]. This definition places the term at the intersection of immunology and oncology, where positive regulators include cytokines such as IL-2, co-stimulatory molecules, and metabolic pathways that sustain effector T cell function [3,4]. Conversely, negative regulators such as PD-1 and its ligands PD-L1/PD-L2 dampen this process, and their inhibition is a cornerstone of modern cancer therapy [2,7]. Understanding the positive regulation of anti-tumor immunity requires integrating antigen presentation, T cell activation, and the tumor microenvironment [4,6]. Recent studies have revealed that tumor cells can actively degrade MHC-I through autophagy, thereby reducing antigen presentation and blunting immune recognition. Additionally, aberrant glycosylation of immune checkpoint molecules like B7H3 can suppress T cell responses, further highlighting the complexity of this regulatory network. Monocytes and other myeloid cells also play a role in stimulating T cells, and tumors can impair this function to evade immunity. Thus, GO:0002839 represents a dynamic and multifaceted process that is central to cancer immunology and immunotherapy research.
positive regulation of immune response to tumor cell At A Glance
| GO ID | GO:0002839 |
|---|---|
| GO term | positive regulation of immune response to tumor cell |
| Ontology | biological_process |
| Synonym | activation of immune response to tumor cell; stimulation of immune response to tumor cell; upregulation of immune response to tumor cell |
| Major function | Enhances the frequency, rate, or extent of immune responses directed against tumor cells |
| Related processes | T cell activation, antigen presentation, cytokine signaling, immune checkpoint regulation |
| Key regulators | PD-1/PD-L1, IL-2, MHC-I/II, B7H3, autophagy, monocyte-mediated stimulation |
| Disease relevance | Cancer immunotherapy, autoimmune conditions, chronic infection |
What Is GO:0002839?
In our own words, GO:0002839 refers to any biological process that enhances the immune response against tumor cells. This includes increasing the activation, proliferation, or effector function of immune cells such as CD8+ T cells, promoting antigen presentation by tumor or antigen-presenting cells, and amplifying cytokine or chemokine signals that recruit and sustain anti-tumor immunity [1,2,3,4]. The term is not limited to a single cell type or mechanism; rather, it captures the integrated outcome of multiple positive regulatory inputs that collectively boost the immune system's ability to detect and destroy cancer cells [6,8].
Why Is positive regulation of immune response to tumor cell Important in Cell Biology?
GO:0002839 is important because it defines the biological processes that can be therapeutically enhanced to treat cancer. Understanding how to positively regulate anti-tumor immunity has led to breakthroughs such as immune checkpoint inhibitors, adoptive T cell therapies, and cancer vaccines [2,7]. Moreover, tumors often evolve mechanisms to suppress this process, such as autophagy-mediated MHC-I degradation or aberrant glycosylation, making it essential to identify the molecular brakes that can be targeted [1,5]. Research into this term also informs the development of biomarkers for patient stratification and the design of combination therapies that convert immunologically cold tumors into hot ones [4,8].
• Provides a framework for understanding how immune checkpoint blockade reinvigorates anti-tumor T cell responses [2,7].
• Highlights the role of antigen presentation machinery, including MHC-I and MHC-II, in tumor immune surveillance [1,6].
• Links metabolic adaptation of CD8+ T cells to their effector function in the tumor microenvironment.
• Reveals how tumor-intrinsic pathways such as autophagy and glycosylation suppress immune recognition [1,5].
• Underscores the importance of myeloid cells, including monocytes, in stimulating T cell responses against tumors.
• Guides the development of CRISPR-based screens to identify positive regulators of anti-tumor immunity [1,5,8].
• Supports the rationale for cytokine therapies such as IL-2 to boost immune responses.
• Informs resistance mechanisms to immunotherapy and potential combination strategies [2,8].
• Facilitates the discovery of novel therapeutic targets within the tumor microenvironment [4,6].
• Enables functional validation of candidate genes using knockout, knock-in, and overexpression models [1,5,8].
What Happens During positive regulation of immune response to tumor cell?
Antigen Presentation and Recognition
In simple terms: Tumor cells display abnormal proteins on their surface that immune cells can recognize as foreign.
The first step in positively regulating an immune response to tumor cells is the presentation of tumor antigens. Tumor cells can present antigens via MHC-I to CD8+ T cells, but this process is often downregulated. Autophagy in pancreatic cancer cells degrades MHC-I, reducing antigen presentation and promoting immune evasion. Conversely, positive regulation can occur when MHC-I expression is restored or when tumor cells express MHC-II, which can directly stimulate CD4+ T cells. The balance between antigen presentation and degradation is a key control point for anti-tumor immunity [1,6].
T Cell Activation and Co-stimulation
In simple terms: Immune T cells need a second signal to become fully activated against tumors.
T cell activation requires both T cell receptor engagement by antigen-MHC complexes and co-stimulatory signals. Positive regulation of anti-tumor immunity involves co-stimulatory molecules such as CD28 binding to B7 ligands on antigen-presenting cells. However, tumors can express aberrantly glycosylated B7H3, which suppresses T cell responses instead of activating them. Additionally, monocyte-mediated T cell stimulation is critical, and tumors can impair this process to evade immunity. Thus, positive regulation encompasses the enhancement of co-stimulation and the removal of inhibitory signals [5,8].
Cytokine Signaling and Effector Function
In simple terms: Cytokines are chemical messengers that boost the immune attack on tumors.
Cytokines such as IL-2 are potent positive regulators of anti-tumor immunity. IL-2 promotes the proliferation, survival, and effector function of CD8+ T cells and natural killer cells. The biology of IL-2 has been harnessed in human therapy, including high-dose IL-2 for metastatic melanoma and renal cell carcinoma. Other cytokines, such as IFN-gamma, also enhance antigen presentation and recruit effector cells. Positive regulation of immune response to tumor cell therefore includes the signaling pathways that amplify these cytokine networks [3,4].
Metabolic Support of Effector T Cells
In simple terms: T cells need energy and building blocks to fight tumors effectively.
The tumor microenvironment imposes metabolic constraints on infiltrating T cells. Positive regulation of anti-tumor immunity requires metabolic adaptations that sustain CD8+ T cell function, such as enhanced glucose uptake, mitochondrial fitness, and amino acid availability. Microenvironment-driven metabolic adaptations guide CD8+ T cell anti-tumor immunity, and interventions that support these pathways can boost immune responses. Thus, metabolic reprogramming is an integral part of positively regulating anti-tumor immunity.
Overcoming Immune Checkpoint Inhibition
In simple terms: Checkpoints are brakes on the immune system that tumors use to shut down attacks.
The PD-1 inhibitory pathway is a major negative regulator of anti-tumor immunity. PD-1 blockade induces responses by inhibiting adaptive immune resistance, effectively removing a brake and thereby positively regulating the immune response to tumor cells [2,7]. The diverse functions of the PD-1 pathway include limiting T cell activation and effector function, and its inhibition restores anti-tumor activity. Therefore, positive regulation of GO:0002839 can be achieved pharmacologically by checkpoint blockade, which unleashes pre-existing anti-tumor immunity.
Key Genes Involved in GO:0002839 positive regulation of immune response to tumor cell
The following genes and proteins are key players in the positive regulation of immune response to tumor cell, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PDCD1 (PD-1) | Inhibitory receptor on T cells; negative regulator of anti-tumor immunity | Target for checkpoint blockade; knockout models show enhanced anti-tumor responses [2,7] |
| CD274 (PD-L1) | Ligand for PD-1; suppresses T cell activation | Blockade or knockout increases immune response to tumors [2,7] |
| IL2 | Cytokine that promotes T cell proliferation and effector function | Used in high-dose therapy; knockout and knock-in models study its role |
| MHC-I (e.g., HLA-A, B, C) | Presents tumor antigens to CD8+ T cells | Autophagy-mediated degradation causes immune evasion; knockout reduces antigen presentation |
| MHC-II (e.g., HLA-DR) | Presents antigens to CD4+ T cells | Tumor expression can be immunostimulatory or immunosuppressive; context-dependent |
| B7H3 (CD276) | Immune checkpoint molecule; aberrant glycosylation suppresses T cells | FUT8-mediated glycosylation impairs anti-tumor immunity; knockout or point mutation studies |
| FUT8 | Glycosyltransferase that adds fucose to B7H3 | Knockout reduces aberrant glycosylation and restores T cell responses |
| ATG5 | Autophagy-related gene required for autophagosome formation | Knockout inhibits MHC-I degradation and enhances antigen presentation |
| ATG7 | Autophagy-related gene; involved in MHC-I degradation | Knockout models show increased immune recognition of tumors |
| CD8A | Marker of cytotoxic T cells; effector cells in anti-tumor immunity | Knockout or depletion models assess T cell contribution [4,7] |
| CD4 | Marker of helper T cells; support anti-tumor immunity | Knockout models evaluate helper T cell function |
| IFNG | Cytokine that enhances antigen presentation and immune activation | Knockout models show impaired tumor rejection |
| GZMB | Granzyme B; mediates target cell killing by CD8+ T cells | Overexpression or knockout models assess cytotoxic function |
| PRF1 | Perforin; pore-forming protein in cytotoxic granules | Knockout models show defective tumor killing |
| CD28 | Co-stimulatory receptor on T cells | Knockout models show impaired T cell activation |
| CD80 (B7-1) | Co-stimulatory ligand for CD28 | Overexpression enhances T cell activation |
| CD86 (B7-2) | Co-stimulatory ligand for CD28 | Overexpression enhances T cell activation |
| SLC2A1 (GLUT1) | Glucose transporter; supports T cell metabolism | Knockout or overexpression models study metabolic support |
How Is positive regulation of immune response to tumor cell Regulated?
The positive regulation of immune response to tumor cell is tightly controlled by a balance of stimulatory and inhibitory signals. The PD-1/PD-L1 axis is a dominant inhibitory pathway; its blockade removes suppression and thereby positively regulates anti-tumor immunity [2,7]. Cytokines such as IL-2 provide positive signals that enhance T cell effector function. Metabolic pathways, including those regulated by mTOR and AMPK, influence T cell fitness in the tumor microenvironment. Tumor-intrinsic mechanisms such as autophagy degrade MHC-I and reduce antigen presentation, acting as a negative regulator of this process. Aberrant glycosylation of B7H3 by FUT8 also suppresses T cell responses, and targeting this pathway can restore positive regulation. Monocytes and other myeloid cells can either stimulate or suppress T cells, and tumors can impair their stimulatory function. Thus, regulation occurs at multiple levels: receptor-ligand interactions, cytokine signaling, metabolic checkpoints, and tumor cell-intrinsic pathways [1,2,3,4,5,8].
positive regulation of immune response to tumor cell and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PDCD1 | Melanoma, lung cancer; checkpoint blockade target | Knockout mice or human T cells with PD-1 knockout; overexpression of PD-1 for resistance studies [2,7] |
| CD274 | Multiple cancers; PD-L1-mediated immune evasion | Knockout tumor cells to reduce PD-L1; knock-in reporters for expression tracking [2,7] |
| ATG5 | Pancreatic cancer; autophagy-mediated MHC-I degradation | Knockout pancreatic cancer cells to restore MHC-I and enhance immune recognition |
| FUT8 | Triple-negative breast cancer; aberrant B7H3 glycosylation | Knockout or point mutation of FUT8 to prevent glycosylation and boost T cell responses |
| IL2 | Metastatic melanoma and renal cell carcinoma; cytokine therapy | Knockout or knock-in models to study IL-2 signaling; overexpression for therapy |
Cancer Immunotherapy and Immune Evasion
GO:0002839 is directly relevant to cancer immunotherapy, where the goal is to enhance the immune response against tumor cells. Checkpoint inhibitors targeting PD-1 or PD-L1 have revolutionized treatment for melanoma, lung cancer, and other malignancies by removing inhibitory brakes [2,7]. However, many tumors resist immunotherapy through mechanisms such as autophagy-mediated MHC-I degradation, which reduces antigen presentation and limits T cell recognition. Aberrant glycosylation of B7H3 in triple-negative breast cancer suppresses immune responses, providing a potential target for intervention. Monocyte-mediated T cell stimulation is also impaired in some tumors, contributing to immune evasion. Understanding these mechanisms is essential for developing combination therapies that convert resistant tumors into responsive ones [1,5,8].
Autoimmunity and Chronic Inflammation
While positive regulation of anti-tumor immunity is beneficial in cancer, excessive or misdirected immune activation can contribute to autoimmune diseases. The same pathways that boost anti-tumor responses, such as co-stimulation and cytokine signaling, can also drive autoimmunity if not properly regulated [2,3]. For example, IL-2 therapy can induce autoimmune side effects, and checkpoint blockade can lead to immune-related adverse events [3,7]. Thus, understanding the positive regulation of immune responses to tumor cells also informs the development of safer immunotherapies with reduced autoimmune toxicity [2,3].
Metabolic Disorders and T Cell Dysfunction
Metabolic adaptations in the tumor microenvironment can impair CD8+ T cell function, effectively reducing positive regulation of anti-tumor immunity. Conditions such as obesity and diabetes can alter systemic metabolism and impact immune cell function, potentially affecting cancer outcomes. Research into metabolic pathways that support T cell effector function may lead to interventions that enhance anti-tumor immunity in metabolically compromised patients.
From positive regulation of immune response to tumor cell-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does knockout of a candidate gene enhance anti-tumor immunity? | CRISPR knockout in tumor cells or T cells followed by co-culture or mouse tumor models [1,5,8] |
| Does a specific point mutation in an immune checkpoint alter its function? | CRISPR point mutation knock-in to create mutant alleles, e.g., in PDCD1 or FUT8 [2,5] |
| Can knock-in of a reporter gene track antigen presentation? | CRISPR knock-in of fluorescent tag into MHC-I or MHC-II loci [1,6] |
| Does overexpression of a co-stimulatory molecule boost T cell activation? | CRISPR overexpression via safe-harbor knock-in or lentiviral transduction |
| What is the role of metabolic genes in T cell effector function? | Knockout or overexpression of SLC2A1, etc., in T cells followed by metabolic assays |
| Can library screening identify novel positive regulators? | Genome-wide CRISPR knockout or activation screens in co-culture systems [1,5,8] |
How to Study the positive regulation of immune response to tumor cell Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screen | Loss-of-function effects on immune-mediated killing | Identify positive regulators of anti-tumor immunity [1,5,8] |
| RNA-seq | Transcriptional changes in immune and tumor cells | Discover gene expression signatures of immune activation [4,6] |
| Flow cytometry | Protein expression and immune cell phenotypes | Validate MHC, checkpoint, and effector molecule changes [2,6,7] |
| In vivo tumor challenge | Tumor growth and survival in immunocompetent hosts | Test causality of candidate genes in anti-tumor immunity [1,5,8] |
| Co-culture cytotoxicity assay | T cell-mediated killing of tumor cells | Assess functional impact of gene edits [1,5] |
| Metabolic assays (Seahorse) | Glycolysis and oxidative phosphorylation | Study metabolic support of T cell effector function |
| ELISA/Luminex | Cytokine secretion (e.g., IL-2, IFN-gamma) | Quantify immune activation [3,4] |
| Immunohistochemistry | Tissue localization of immune cells and markers | Evaluate tumor microenvironment in situ [6,8] |
CRISPR Knockout Screens
Genome-wide CRISPR knockout screens are powerful tools to identify genes that positively regulate immune response to tumor cells. By co-culturing tumor cells with T cells and selecting for survivors, researchers can discover genes whose loss enhances or impairs immune-mediated killing [1,5,8]. Such screens have revealed autophagy genes like ATG5 and ATG7 as negative regulators of antigen presentation, and FUT8 as a modulator of B7H3 glycosylation [1,5].
RNA Sequencing and Transcriptomics
RNA-seq can measure changes in gene expression associated with positive regulation of anti-tumor immunity. For example, comparing tumors with high versus low immune infiltration can reveal signatures of T cell activation, cytokine signaling, and antigen presentation [4,6]. Transcriptomic profiling of CRISPR knockout models can uncover pathways affected by candidate genes [1,5].
Flow Cytometry and Immunophenotyping
Flow cytometry is used to quantify immune cell populations, activation markers, and effector molecules such as IFN-gamma and granzyme B. It can assess MHC-I and MHC-II expression on tumor cells, PD-L1 levels, and T cell exhaustion markers [2,6,7]. This method is essential for validating functional changes in CRISPR-edited cells [1,5].
In Vivo Tumor Models
Mouse tumor models, including syngeneic and xenograft models, allow assessment of positive regulation of anti-tumor immunity in a physiological context. CRISPR-edited tumor cells or T cells can be implanted to test whether specific gene edits enhance tumor rejection [1,5,8]. These models are critical for translating in vitro findings to potential therapies [2,7].
How CRISPR Can Be Used to Study GO:0002839 positive regulation of immune response to tumor cell
Knockout
CRISPR knockout is used to delete genes hypothesized to regulate anti-tumor immunity. For example, knocking out ATG5 or ATG7 in pancreatic cancer cells prevents autophagy-mediated MHC-I degradation, thereby enhancing antigen presentation and T cell recognition. Knocking out FUT8 reduces aberrant glycosylation of B7H3 and restores T cell responses in triple-negative breast cancer models. Knockout of PD-1 in T cells enhances their effector function and persistence [2,7]. These models are essential for establishing causal roles of specific genes in GO:0002839.
Point Mutation
CRISPR point mutation knock-in allows the introduction of specific amino acid changes to study structure-function relationships. For instance, mutating glycosylation sites on B7H3 can prevent its suppressive function and boost anti-tumor immunity. Point mutations in PD-1 that disrupt ligand binding can elucidate signaling mechanisms. Such models are valuable for understanding how subtle genetic changes affect the positive regulation of immune responses to tumor cells.
Knock-in
CRISPR knock-in can be used to insert reporter genes, tags, or human disease alleles. For example, knocking in a fluorescent tag into the MHC-I locus allows tracking of antigen presentation in live cells. Knock-in of a human PD-1 allele into mouse models enables testing of human-specific therapeutics. These models facilitate precise monitoring of immune regulatory processes.
Overexpression
CRISPR overexpression via safe-harbor knock-in or CRISPR activation (CRISPRa) can boost expression of positive regulators. Overexpressing IL-2 or co-stimulatory molecules such as CD80/CD86 can enhance T cell activation and anti-tumor immunity [3,5]. Overexpression of metabolic genes like SLC2A1 can improve T cell fitness in the tumor microenvironment. These approaches help identify sufficiency of candidate genes in promoting immune responses.
How EDITGENE Supports positive regulation of immune response to tumor cell Research
Researchers studying positive regulation of immune response to tumor cell-related genes often need to determine whether a candidate gene is causally involved in enhancing or suppressing anti-tumor immunity. EDITGENE provides a comprehensive suite of CRISPR services to enable such functional studies, from knockout to overexpression and library screening.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of immune response to tumor cell research.
Frequently Asked Questions About positive regulation of immune response to tumor cell
What is GO:0002839?
GO:0002839 is the Gene Ontology term for positive regulation of immune response to tumor cell, defined as any process that activates or increases the frequency, rate, or extent of an immune response directed against tumor cells [1,2].
What genes are involved in positive regulation of immune response to tumor cell?
Key genes include PDCD1 (PD-1), CD274 (PD-L1), IL2, MHC-I and MHC-II genes, B7H3, FUT8, ATG5, ATG7, and metabolic genes such as SLC2A1 [1,2,3,4,5,6,8].
How do tumors evade the immune response?
Tumors can evade immune responses by degrading MHC-I through autophagy, expressing aberrantly glycosylated B7H3, impairing monocyte-mediated T cell stimulation, and upregulating checkpoint ligands like PD-L1 [1,5,8].
What is the role of PD-1 in anti-tumor immunity?
PD-1 is an inhibitory receptor on T cells that dampens anti-tumor immunity; its blockade with antibodies restores T cell effector function and promotes tumor rejection [2,7].
How can CRISPR be used to study positive regulation of immune response to tumor cell?
CRISPR knockout, knock-in, point mutation, and overexpression models allow functional dissection of genes involved in anti-tumor immunity, and CRISPR screens can identify novel regulators [1,5,8].
What diseases are associated with defects in anti-tumor immunity?
Defects in anti-tumor immunity contribute to cancer progression, particularly in melanoma, pancreatic cancer, and triple-negative breast cancer, and can also influence autoimmune and metabolic disorders [1,2,3,4,5,7].
What is the role of IL-2 in anti-tumor immunity?
IL-2 is a cytokine that promotes T cell proliferation, survival, and effector function, and it has been used therapeutically in metastatic melanoma and renal cell carcinoma.
How does autophagy affect immune response to tumors?
Autophagy in tumor cells can degrade MHC-I, reducing antigen presentation and helping tumors evade immune detection; inhibiting autophagy can restore immune recognition.
What is the significance of B7H3 glycosylation in cancer?
Aberrant N-glycosylation of B7H3 by FUT8 suppresses T cell responses in triple-negative breast cancer; targeting this pathway can enhance anti-tumor immunity.
What methods are used to study positive regulation of immune response to tumor cell?
Common methods include CRISPR screens, RNA-seq, flow cytometry, in vivo tumor models, co-culture cytotoxicity assays, and metabolic assays [1,4,5,6,7,8].
Conclusion
GO:0002839, positive regulation of immune response to tumor cell, is a central biological process in cancer immunology. It encompasses diverse mechanisms, from antigen presentation and co-stimulation to cytokine signaling and metabolic support, all of which can be harnessed to improve cancer immunotherapy [1,2,3,4,5,6,7,8]. Understanding how tumors evade these positive regulatory pathways is essential for developing next-generation treatments. CRISPR-based models and screens are invaluable for identifying and validating causal genes within this process, and EDITGENE provides the tools and expertise to accelerate such research.
References
- 1. Yamamoto K et al.. 2020. Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I.. Nature 581(7806):100-105 PMID: 32376951
- 2. Sharpe AH et al.. 2018. The diverse functions of the PD1 inhibitory pathway.. Nat Rev Immunol 18(3):153-167 PMID: 28990585
- 3. Spolski R et al.. 2018. Biology and regulation of IL-2: from molecular mechanisms to human therapy.. Nat Rev Immunol 18(10):648-659 PMID: 30089912
- 4. Park J et al.. 2023. Microenvironment-driven metabolic adaptations guiding CD8(+) T cell anti-tumor immunity.. Immunity 56(1):32-42 PMID: 36630916
- 5. Huang Y et al.. 2021. FUT8-mediated aberrant N-glycosylation of B7H3 suppresses the immune response in triple-negative breast cancer.. Nat Commun 12(1):2672 PMID: 33976130
- 6. Axelrod ML et al.. 2019. Biological Consequences of MHC-II Expression by Tumor Cells in Cancer.. Clin Cancer Res 25(8):2392-2402 PMID: 30463850
- 7. Tumeh PC et al.. 2014. PD-1 blockade induces responses by inhibiting adaptive immune resistance.. Nature 515(7528):568-71 PMID: 25428505
- 8. Elewaut A et al.. 2025. Cancer cells impair monocyte-mediated T cell stimulation to evade immunity.. Nature 637(8046):716-725 PMID: 39604727
